| CPC A61K 51/0497 (2013.01) [A61K 47/55 (2017.08); A61K 49/0032 (2013.01); A61K 49/0043 (2013.01); A61K 49/0052 (2013.01); G01N 33/56966 (2013.01)] | 22 Claims |
|
1. A conjugate, or a pharmaceutically acceptable salt thereof, having a structure
B-L-X,
wherein B is a fibroblast activation protein (FAP) inhibitor; is of the formula:
![]() wherein each of R1 and R2 is independently selected from the group consisting of hydrogen, halogen, and C1-C4 alkyl; R3 is a C1-C4 alkyl, nitrile, or isonitrile;
and each of R4, R5, and R6 is independently selected from the group consisting of hydrogen, halogen, and C1-C4 alkyl; and n is an integer from 1 to 8
L is a bivalent linker comprising at least one amino acid selected from the group consisting of Glu and Cys, or a derivative thereof; and
X comprises a near infrared (NIR) dye, a radioactive imaging agent, or a therapeutic agent effective against cancer cells and/or cancer-associated fibroblasts (CAF),
wherein the linker further comprises a fragment of the formula
![]() wherein
m is an integer from 0 to 9;
p is an integer from 3 to 10; and
q is an integer from 3 to 100.
|